---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-133766"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:22:02.033031+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Seres Q1 net loss $40.1M, VOWST sales $10.1M; SER-155 data expected Q3

## Summary
- Net loss $40.1M vs $71.2M YoY; VOWST net sales $10.1M (642 units).
- Received ~1,411 VOWST enrollment forms, ~1,083 new patient starts in Q1.
- SER-155 Phase 1b Cohort 2 data readout expected end of Q3 2024.
- Cash $111.2M; expects runway into Q4 2024; may draw $45M debt tranche or use ATM.
- Marella Thorell appointed EVP and CFO following David Arkowitz's retirement.

## SEC filing metadata
- accession: 0001193125-24-133766
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312524133766/0001193125-24-133766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312524133766/d812139d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-133766
- JSON: https://secwatch.observer/filing/0001193125-24-133766.json
- Plain text: https://secwatch.observer/filing/0001193125-24-133766.txt

## Key facts
- Earnings Releases
  Seres Therapeutics, Inc. reported first quarter 2024 results: revenue $10.1 million, net income $40.1 million.
  - Period: first quarter 2024
  - Revenue: $10.1 million
  - Net income: $40.1 million
  - Result: reported results
  source text: BUSINESS UPDATES Continued market adoption of VOWST ® with approximately 1,411 patient enrollment forms received, approximately 1,083 new patient starts, and net sales of $10.1 million during Q1 2024, and accelerated net sales in March and April SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout expected end of Q3 2024 Further microbiome therapeutic
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312524133766/0001193125-24-133766-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.